Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00194818 · ClinicalTrials.gov registry record · Phase 4
Asacol Dosing Study for Active Ulcerative Colitis
A Phase 4 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT00194818 is a Phase 4 study that has completed, run by University of Washington. The registered enrollment target is 7 participants.
The verdict
NCT00194818, a Phase 4 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
We, the investigators at University of Washington, plan on evaluating the effect of open label Asacol at a dose of 4.8 grams/day divided BID (twice per day) or TID (three times per day) on its ability to induce remission in patients with mild to moderately active ulcerative colitis. We hypothesize that both regimens will have the same efficacy and no difference in side effects.
Interventions
- DRUG Asacol (mesalamine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2003-06 |
| Est. Completion | 2007-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00194818
The ClinicalTrials.gov registry entry for NCT00194818 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Asacol (mesalamine) is the first listed.
NCT00194818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00194818 about?
NCT00194818 is a clinical study titled "Asacol Dosing Study for Active Ulcerative Colitis". We, the investigators at University of Washington, plan on evaluating the effect of open label Asacol at a dose of 4.8 grams/day divided BID (twice per day) or TID (three times per day) on its ability to induce remission in patients with mild to moderately active ulcerative colitis. We hypothesize t...
What is the current status of trial NCT00194818?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2003-06. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00194818?
The interventions under investigation include: Asacol (mesalamine) (DRUG).
Who is sponsoring clinical trial NCT00194818?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.